Cancer immunotherapy works by reactivating the immune system's ability to recognize and destroy cancer cells by blocking inhibitory signals, particularly the PD-1/PD-L1 pathway[1][2]. But new research has revealed that cancer cells have a mechanism to circumvent this treatment: they can package the PD-L1 protein into small particles circulating in the body, weakening the effect of immunotherapy[1]. Scientists in Japan have identified that this process is controlled by the protein UBL3, which was not well known until now[1]. A surprising finding is that commonly used cholesterol-lowering drugs – statins – can stop this process[1]. Táto objavená cesta vysvetľuje, prečo mnohé nádory napriek imunoterapii nachádzajú spôsoby, ako uniknúť imunitnému dozoru[1]. Research suggests the potential for a combination approach where immunotherapy could be combined with statins to increase its effectiveness[1].